| Document |
Document Title |
|
WO/2004/000833A1 |
The present invention provides a facile process for the preparation of tri-and tetra-substituted pyrimidines. The process is useful for preparing inhibitors of protein kinases, especially Aurora kinase. These inhibitors are useful for tr...
|
|
WO/2004/000804A1 |
Disclosed are ring-substituted diphenyl azetidinones of formula I, a method for the production thereof, medicaments containing said compounds, and the use thereof for treating hyperlipidemia, arteriosclerosis, and hypercholesterolemia.
|
|
WO/2004/000840A2 |
Carbamates of formula (I) or pharmaceutically acceptable salts thereof, including quaternary ammonium salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their ...
|
|
WO/2003/106430A1 |
Compounds of formula I are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therap...
|
|
WO/2003/103567A2 |
The invention relates to compounds of the general formula (I) in which R i, A, n, B and Z are as defined in Claim 1. These compounds can be used for the preparation of antioxidant medicinal products that function as free-radical scavenge...
|
|
WO/2003/104227A1 |
The invention relates to the novel 2-heteroaryl carboxamides according to formula (I), wherein R1 represents 1-aza-bicyclo [2.2.2]oct-3-yl, which is optionally replaced via the nitrogen atom by a group selected from the family C1-C4 alky...
|
|
WO/2003/101987A1 |
This invention relates to novel 3-substituted quinuclidine derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacol...
|
|
WO/2003/094830A2 |
This invention relates to novel azacyclic ethynyl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological pr...
|
|
WO/2003/093235A1 |
Novel compounds of formula (I), wherein D, W, X, Y, T and R1 have the meanings as cited in Patent Claim 1, are inhibitors of coagulation factor Xa and can be used for the prophylaxis and/or therapy of thromboembolic diseases and for the ...
|
|
WO/2003/093254A1 |
The invention relates to novel compounds of formula (I), wherein R, R1, R1', X and T have the meaning given in patent claim 1. Said novel compounds are inhibitors of coagulation factor Xa and can be used for the prophylaxis and/or therap...
|
|
WO/2003/090680A2 |
The present invention related to certain phenyl derivatives that are activators of caspases and inducers of apoptosis, pharmaceutical composition comprising these compounds and method of treating cancer utilizing these compounds.
|
|
WO/2003/091207A2 |
This invention provides a method of preparing amine stereoisomers, which comprises stereoselectively reducing a sulfinylimine that bears on the sulfmyl group a residue of an alcohol, thiol or amine, or reacting a sulfmylimine stereoisome...
|
|
WO/2003/089439A1 |
The invention relates to bicyclic heterocycles of general formula (I), in which Ra, Rb, Rc, A, B, C, D, E and X are defined as in Claim 1, to tautomers, stereoisomers, mixtures and salts thereof, particularly their physiologically compat...
|
|
WO/2003/087304A2 |
Compounds of formula (I) possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention...
|
|
WO/2003/087095A1 |
Organic compounds having the formulas (I) and (II) are provided where the variables have the values described herein. Medicaments include an anti-cancer drug selected from 5-FU or CPT 11 and a compound of formula (I) or formula (II), a t...
|
|
WO/2003/086282A2 |
The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one...
|
|
WO/2003/087104A1 |
Compounds of formula I : and pharmaceutically-acceptable salts thereof, wherein Ar and R are as defined in the specification, compositions containing such compounds and the use of such compounds and compositions for use in therapy.
|
|
WO/2003/084533A1 |
The invention relates to novel compounds of formula (I) wherein D, M, W, X, Y, T and R1 have the designation cited in patent claim 1. According to the invention, said compounds are inhibitors of the coagulation factor Xa and can be used ...
|
|
WO/2003/082272A1 |
New substituted benz-azole compounds of formula (I), compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with ...
|
|
WO/2003/082808A1 |
Because of having an Rho kinase inhibitory effect, compounds represented by the following general formula (1), prodrugs thereof or pharmaceutically acceptable salts of the same are useful in treating diseases such as hypertension the pat...
|
|
WO/2003/082350A2 |
The present invention is concerned with radiolabelled quinoline and quinolinone derivatives according Formula (I-A)* or (I-B)* showing metabotropic glutamate receptor antagonistic activity, in particular mGlu1 receptor activity, and thei...
|
|
WO/2003/078430A1 |
The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, l...
|
|
WO/2003/078431A1 |
The invention relates to novel 1-aza-bicyclic N-biarylamides, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning...
|
|
WO/2003/075921A2 |
This invention provides certain compounds of formula I wherein A1 is O, S or -N(R2)-, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds ...
|
|
WO/2003/076406A1 |
Compounds of formula (I) in which each of the phenyl rings represented is optionally substituted one or more times; n represents an integer selected from 0, 1, 2, 3, 4 and 5; W represents -CO-or -SO2-; Z represents H; alkyl; aryl; or ary...
|
|
WO/2003/072578A1 |
The invention provides compounds of Formula I: (1) wherein Azabicyclo is (2) W is a six-membered heterocyclic ring system having 1-2 nitrogen atoms or a 10-membered bicyclic-six-six-fused-ring system having up to two nitrogen atoms withi...
|
|
WO/2003/070727A1 |
Selected thiazolyl urea compounds of formula (VI) are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharma...
|
|
WO/2003/070728A2 |
The invention provides compounds of Formula I: (I). These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals to tr...
|
|
WO/2003/070731A2 |
The invention provides compounds of Formula (I), wherein Azabicyclo is (II), W is (III). These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in ...
|
|
WO/2003/068749A1 |
Certain compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, P, X, Y, q, r ans s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition...
|
|
WO/2003/066099A1 |
An antidementia drug containing a BEC1 potassium channel inhibitor as the active ingredient. It is proved that the BEC1 potassium channel inhibitor has an effect of ameliorating learning disability and is useful as a preventive or a reme...
|
|
WO/2003/064420A1 |
A method for kinetic optical resolution of carboxylic acid derivatives with a specific optically active catalyst is provided which comprises reacting a racemic or diasteromeric mixture of a carboxylic acid derivative of the general formu...
|
|
WO/2003/062233A1 |
A 2−acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c−mpl−Ba&sol F3 cells and an activity of increasing platelets based on the effect of promoting the for...
|
|
WO/2003/055878A1 |
The invention relates to novel 2-heteroarylcarboxylic acid amides, methods for the production thereof in addition to the use thereof for the production of medicaments for the treatment and/or the prophylaxis of illnesses and for the impr...
|
|
WO/2003/053966A2 |
Carbamate of general formula (I), wherein R1, R2 and R3 are H, OH, NO2, SH, CN, F, Cl, Br, I, COOH, CONH2, (C1-C4)-alkoxycarbonyl, (C1C4)-alkylsulfanyl, (C1-C4)-alkylsulfinyl, (C1C4)-alkylsulfonyl, (C1-C4)-alkoxyl optionally substituted ...
|
|
WO/2003/051874A1 |
The invention relates to novel bicyclic N-arylamides, to a method for the production thereof, and to the use of the same for producing pharmaceuticals for the treatment and/or prophylaxis of diseases and for improving perception, power o...
|
|
WO/2003/050088A1 |
This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparat...
|
|
WO/2003/049741A1 |
The present invention relates to the use of compounds of the general formula (I) and to pharmaceutically acceptable acid addition salts thereof for the manufacture of medicaments for the treatment of diseases, related to the adenosine A2...
|
|
WO/2003/045940A2 |
The present invention provides compounds of Formula (I): wherein X, R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds. The invention also provi...
|
|
WO/2003/045313A2 |
The present invention is concerned with compounds of the general Formula I : and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists.As such, ...
|
|
WO/2003/045948A1 |
A novel asymmetric phase transfer catalyst and a method for producing alpha-amino acids using the same are disclosed. Using the catalyst in the production of alpha-amino acids, optically active alpha-amino acids can easily be produced wi...
|
|
WO/2003/043991A1 |
The invention relates to novel heteroaryl carboxylic acid amides, a method for producing the same and the use thereof for producing pharmaceuticals for the treatment and/or prophylaxis of diseases and for improving perception, power of c...
|
|
WO/2003/042210A1 |
The invention provides compounds of Formula (I): wherein Azabicyclo is any of Formulae (l, II, III, IV, V, VI). These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof....
|
|
WO/2003/042176A1 |
An azabicyclo compound (I) or a salt thereof which each has excellent inhibitory activity against matrix metalloproteases (MMPs) and is useful in medicinal compositions, cosmetic compositions, and skin preparations. In the formula (I), R...
|
|
WO/2003/040096A2 |
Disclosed are compounds of the formula (I), wherein the variables RN, RC, R1, R25, R2, and R3 are as defined herein. These compounds have activity as inhibitors of betasecretase and are therefore useful in treating a variety of discorder...
|
|
WO/2003/040147A1 |
The invention provides compounds of Formula (I): Azabicyclo-N(R¿1?)-C(=X)-W These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula (I) are usef...
|
|
WO/2003/037896A1 |
The invention provides compounds of Formula (I), wherein Azabicyclo is I, II, III, IV, V, or VI; W?0¿ is a bicyclic moiety and is (a), (b) or (c). These compounds may be in the form of pharmaceutical salts or compositions, may be in pur...
|
|
WO/2003/033472A1 |
The invention provides novel compounds which exhibit an inhibitory activity against autophosphorylation of FGF receptor family and can inhibit the proliferation of cancer cells through oral or intravenous administration, specifically com...
|
|
WO/2003/033476A1 |
A compound of formula (Ia) comprising a pharmaceutically acceptable salt or solvate thereof, formulations, processes of preparing, and methods of administering to mammals are provided
|
|
WO/2003/033495A1 |
The invention concerns quinuclidine derivatives of formula I or II wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention_show high affinities for m3 and/or m...
|
